Mohamad-Samer Mouksassi
Overview
Explore the profile of Mohamad-Samer Mouksassi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marier J, Teuscher N, Mouksassi M
CPT Pharmacometrics Syst Pharmacol
. 2022 Jun;
11(10):1283-1293.
PMID: 35670230
The current tutorial describes why forest plots are needed for an effective communication of covariates effects, how they are constructed, and how they should be presented. Simulation-based methodologies allowing the...
2.
Mwandigha L, Fraser K, Racine-Poon A, Mouksassi M, Ghani A
Int J Epidemiol
. 2020 Feb;
49(3):954-962.
PMID: 32011684
Background: Cluster randomized trials (CRTs) are increasingly used to study the efficacy of interventions targeted at the population level. Formulae exist to calculate sample sizes for CRTs, but they assume...
3.
Skinner-Robertson S, Mouksassi M, Varin F
Pain Physician
. 2018 Jul;
21(4):363-372.
PMID: 30045593
Background: Understanding analgesic pharmacodynamics (PD) in the elderly is key to optimising pain management. Electrically stimulated pain models (ESPM) permit assessment of pain responses in humans. C and A-delta sensory...
4.
Perrone R, Mouksassi M, Romero K, Czerwiec F, Chapman A, Gitomer B, et al.
Kidney Int Rep
. 2017 Nov;
2(3):451-460.
PMID: 29142972
Introduction: Total kidney volume (TKV) is a promising imaging biomarker for tracking and predicting the natural history of patients with autosomal dominant polycystic kidney disease. Methods: A drug development tool...
5.
Perrone R, Mouksassi M, Romero K, Czerwiec F, Chapman A, Gitomer B, et al.
Kidney Int Rep
. 2017 Nov;
2(3):442-450.
PMID: 29142971
Introduction: Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. TKV is a promising imaging biomarker for tracking and predicting the natural history of autosomal dominant polycystic...
6.
Mouksassi M, Marier J, Bax L, Osawa Y, Tsuruta K
Clin Pharmacol Drug Dev
. 2016 May;
4(3):210-7.
PMID: 27140801
Thrombomodulin alfa is a soluble recombinant human thrombomodulin that was reported to enhance the reversal of disseminated intravascular coagulation (DIC) in subjects with sepsis or hematologic malignancy and reduce mortality...
7.
Gosselin N, Mouksassi M, Lu J, Hsu C
Clin Pharmacol Drug Dev
. 2016 May;
4(6):463-72.
PMID: 27137719
Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population pharmacokinetic (POPPK) modeling of motesanib and M4, an active metabolite, was performed to assess sources...
8.
Marier J, Mouksassi M, Gosselin N, Li J
Clin Pharmacol Drug Dev
. 2016 Apr;
3(4):297-304.
PMID: 27128836
Dutogliptin is a selective dipeptidyl peptidase-4 inhibitor shown to be efficacious and safe in patients with type 2 diabetes mellitus (T2DM). Population pharmacokinetic (PK) analysis of dutogliptin was performed based...
9.
Zhu M, Gosselin N, Kuchimanchi M, Johnson J, McCaffery I, Mouksassi M, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
2(4):367-78.
PMID: 27121941
Ganitumab is an investigational, fully human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor (IGF1R) that has shown trends towards improved progression-free survival and overall survival in a phase...
10.
Ouellet D, Kassir N, Chiu J, Mouksassi M, Leonowens C, Cox D, et al.
Cancer Chemother Pharmacol
. 2016 Mar;
77(4):807-17.
PMID: 26940938
Purpose: To characterize the pharmacokinetics of oral trametinib, a first in class MEK inhibitor, identify covariates, and describe the relationship between exposure and clinical effects in patients with BRAF V600...